Mechanisms Underlying the Greater Efficacy of Robot-Assisted Gait Rehabilitation Versus Conventional Therapy Combined With Botulinum Toxin Injection of the Triceps Surae in Individuals With Chronic Post-Stroke Impairments (NEUROBOST)
Stroke is a leading cause of long-term disability in adults. Many people who have had a stroke continue to experience difficulty walking because of muscle weakness and spasticity, which can limit their mobility and quality of life.
Botulinum toxin injections are commonly used to reduce spasticity in specific muscles, such as the calf muscles. Rehabilitation is then used to improve walking ability. Robot-assisted gait rehabilitation allows patients to practice walking intensively and repeatedly, with assistance adjusted to their needs. Previous research from our team has shown that robot-assisted gait rehabilitation may improve walking ability more than conventional physical therapy when combined with botulinum toxin injections.
The purpose of this study is to better understand why robot-assisted gait rehabilitation may be more effective than conventional gait rehabilitation after botulinum toxin treatment in people with chronic stroke. The study will examine changes in walking patterns, muscle activity, and brain activity during and after rehabilitation. Brain activity and brain connections will be assessed using non-invasive methods, including functional near-infrared spectroscopy (fNIRS), electroencephalography (EEG), and magnetic resonance imaging (MRI).
The study may help identify how the brain and body adapt to rehabilitation and may contribute to developing more personalized rehabilitation programs for people living with long-term effects of stroke.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Stroke is a major cause of acquired motor disability in adults. In the chronic phase after stroke, persistent motor impairment is frequently associated with spastic paresis, altered motor control, and maladaptive or compensatory reorganization of the central nervous system. Spasticity may contribute substantially to gait impairment and reduced mobility, thereby affecting functional independence and quality of life.
Botulinum toxin type A (BoNT-A) is an established treatment for focal spasticity after stroke. Intramuscular injection into the triceps surae reduces excessive muscle activity through its action at the neuromuscular junction and can temporarily improve the mechanical conditions for walking. In addition to these peripheral effects, BoNT-A may also indirectly influence central motor networks by modifying proprioceptive and afferent sensory input, potentially promoting cortical reorganization.
Following BoNT-A injection, intensive rehabilitation is required to optimize functional recovery. Robot-assisted gait rehabilitation provides a means of delivering intensive, repetitive, task-specific gait practice, with partial body-weight support and adjustable motor assistance. This approach may allow patients to perform a greater number of gait cycles and to train at higher walking speeds than conventional gait therapy. Previous studies have suggested that robot-assisted gait rehabilitation may improve gait performance, propulsion, gait symmetry, and motor coordination. In a previous study conducted by our research team, robot-assisted gait rehabilitation performed after BoNT-A injection into the triceps surae resulted in a significantly greater improvement in 6-minute walk distance than conventional gait rehabilitation.
The present study aims to investigate the neurophysiological and biomechanical mechanisms underlying the potentially greater benefit of robot-assisted gait rehabilitation compared with conventional gait rehabilitation following BoNT-A treatment in individuals with chronic stroke.
The study will characterize changes in gait performance and gait biomechanics, including spatiotemporal parameters, lower-limb joint kinematics, ground reaction forces, propulsion, and muscle activation patterns. These measurements will be used to determine whether specific changes in gait mechanics and neuromuscular coordination are associated with the greater improvement observed following robot-assisted rehabilitation.
In parallel, the study will investigate changes in brain activity and functional organization associated with rehabilitation. Functional near-infrared spectroscopy (fNIRS) will be used to assess cortical activation during walking. Electroencephalography (EEG) will be used to characterize cortical electrical activity and functional connectivity, with particular attention to changes in frontoparietal and motor networks. Resting-state functional magnetic resonance imaging (fMRI) and diffusion MRI will be used to assess functional and structural brain connectivity, respectively, as well as lesion characteristics and the organization of motor networks.
A particular focus will be placed on changes in the lateralization and organization of motor cortical activity following rehabilitation. The study will test the hypothesis that robot-assisted gait rehabilitation induces more effective neuroplastic adaptations than conventional gait rehabilitation after BoNT-A treatment. These adaptations are expected to involve a shift toward more efficient recruitment and functional organization of ipsilesional motor regions, together with changes in interhemispheric and network-level connectivity.
The study will also investigate whether central effects of BoNT-A can be detected through changes in cortical activity, including modifications of ipsilesional posterior parietal cortex activity previously reported after BoNT-A treatment.
By combining complementary neurophysiological, neuroimaging, biomechanical, and clinical measures, the study aims to identify mechanisms associated with improved walking recovery after BoNT-A combined with robot-assisted gait rehabilitation. An additional objective is to identify quantitative biomarkers that may help predict which individuals are most likely to benefit from this rehabilitation strategy and, ultimately, contribute to more individualized rehabilitation approaches for people with chronic post-stroke motor impairment.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Maëva COTINAT, MD
- Número de telefone: +33 4 91 74 20 00
- E-mail: Maeva.cotinat@ap-hm.fr
Estude backup de contato
- Nome: Laurent BENSOUSSAN, MD
- E-mail: laurent.bensoussan@ap-hm.fr
Locais de estudo
-
-
-
Marseille, França
- UGECAM IUR Valmante Sud
-
Contato:
- Laurent BENSOUSSAN, MD
- Número de telefone: +33 4 88 22 86 99
- E-mail: laurent.bensoussan@ap-hm.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults with hemiparesis.
- Affiliated with a national or public health insurance system.
- Able and willing to provide written informed consent after receiving information about the purpose, procedures, and potential risks of the study.
- At least 6 months after a unilateral stroke.
- Presence of triceps surae spasticity causing impaired gait and treatment with botulinum toxin type A (BoNT-A) as part of routine care, with a stable dose for at least 2 treatment cycles.
- Able to walk for 6 minutes; walking speed <0.8 m/s on the 10-Meter Walk Test.
Exclusion Criteria:
- Cognitive impairment preventing the participant from providing informed consent.
- Triceps surae spasticity >3/5 on the Modified Ashworth Scale.
- Any contraindication to physical exercise, robot-assisted gait rehabilitation using the Lokomat, or MRI.
- Claustrophobia or fear of confined spaces.
- Individuals deprived of liberty by judicial or administrative decision, or under legal guardianship.
- Inability to complete all study procedures.
- Pregnancy, breastfeeding, or plans to become pregnant during the study period.
- Concurrent participation in another research study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Robot-Assisted Gait Rehabilitation
Participants receive robot-assisted gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of intensive, repetitive gait training using a robotic device, with adjustable assistance and body-weight support as appropriate. |
Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.
Outros nomes:
The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.
Outros nomes:
Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.
Outros nomes:
Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.
Outros nomes:
Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.
Outros nomes:
|
|
Comparador Ativo: Conventional Gait Rehabilitation
Participants receive conventional gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of therapist-guided gait training and conventional physical therapy according to standard clinical practice. |
Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.
Outros nomes:
The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.
Outros nomes:
Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.
Outros nomes:
Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.
Outros nomes:
Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in the Lateralization Index of Nodal Degree in the Paracentral Lobules
Prazo: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
The primary outcome measure is the between-group difference in the organization of motor functional brain networks following botulinum toxin type A (BoNT-A) treatment of spasticity in the triceps surae, comparing robot-assisted gait rehabilitation with conventional gait rehabilitation. At rest, functional brain network organization will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary resting-state parameter will be the lateralization index (Lik) of nodal degree (k) in the paracentral lobules ipsilateral and contralateral to the stroke lesion. The Lik will be used to quantify the relative distribution of nodal connectivity between the two hemispheres. |
Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
|
Difference in the Lateralization Index of Activation in the Sensorimotor Cortex Derived From fNIRS Data
Prazo: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
The lateralization index of cortical activation in the sensorimotor cortex will be calculated from functional near-infrared spectroscopy (fNIRS) data collected during walking. The outcome measure will assess the difference in the lateralization of sensorimotor cortical activation between robot-assisted gait rehabilitation and conventional gait rehabilitation following botulinum toxin type A treatment of spasticity in the triceps surae. Higher or lower lateralization index values will indicate a relative predominance of activation in one cerebral hemisphere. |
Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Lateralization of Brain Activation in Locomotor-Related Cortical Areas During Walking
Prazo: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
The lateralization of brain activation in cortical areas involved in locomotion, including the prefrontal cortex (PFC), premotor cortex (PMC), and supplementary motor area (SMA), will be assessed during walking using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Differences in the lateralization of cortical activation between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups will be evaluated following botulinum toxin type A treatment of spasticity in the triceps surae. |
Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
|
Change in Resting-State Activity of the Ipsilesional Posterior Parietal Cortex
Prazo: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in activity of the posterior parietal cortex ipsilateral to the stroke lesion. The change in resting-state activity will be compared between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups following botulinum toxin type A treatment of spasticity in the triceps surae. |
Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças musculoesqueléticas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Doenças Musculares
- Hipertonia muscular
- Manifestações Neuromusculares
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Espasticidade muscular
- Derrame
- Paresia
- Técnicas de investigação
- Técnicas de química, analíticas
- Análise de espectro
- Espectroscopia de ressonância magnética
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2025-A01470-49
- 2025-A01470-49 (Outro identificador: ANSM)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .